Quanterix Co. (NASDAQ:QTRX - Free Report) - Stock analysts at Leerink Partnrs issued their Q1 2026 earnings per share estimates for shares of Quanterix in a research report issued to clients and investors on Tuesday, January 7th. Leerink Partnrs analyst P. Souda forecasts that the company will post earnings per share of ($0.25) for the quarter. The consensus estimate for Quanterix's current full-year earnings is ($0.88) per share. Leerink Partnrs also issued estimates for Quanterix's Q2 2026 earnings at ($0.20) EPS, Q3 2026 earnings at ($0.13) EPS and Q4 2026 earnings at ($0.16) EPS.
Separately, TD Cowen boosted their target price on Quanterix from $13.50 to $16.00 and gave the stock a "hold" rating in a research note on Wednesday, November 13th.
Get Our Latest Stock Report on Quanterix
Quanterix Trading Down 0.5 %
QTRX stock traded down $0.06 during trading on Wednesday, hitting $11.73. 357,166 shares of the company's stock were exchanged, compared to its average volume of 332,573. The business has a 50-day moving average price of $12.05 and a two-hundred day moving average price of $12.70. The stock has a market capitalization of $451.89 million, a price-to-earnings ratio of -11.17 and a beta of 1.33. Quanterix has a 52-week low of $9.87 and a 52-week high of $29.70.
Institutional Inflows and Outflows
Institutional investors have recently added to or reduced their stakes in the company. nVerses Capital LLC acquired a new position in Quanterix during the third quarter worth approximately $60,000. Peapack Gladstone Financial Corp acquired a new position in Quanterix during the third quarter worth approximately $131,000. SG Americas Securities LLC acquired a new position in Quanterix during the third quarter worth approximately $139,000. Canada Pension Plan Investment Board acquired a new position in shares of Quanterix in the second quarter valued at approximately $140,000. Finally, Hsbc Holdings PLC increased its holdings in shares of Quanterix by 34.7% in the second quarter. Hsbc Holdings PLC now owns 12,738 shares of the company's stock valued at $164,000 after purchasing an additional 3,279 shares during the period. Institutional investors and hedge funds own 86.48% of the company's stock.
About Quanterix
(
Get Free Report)
Quanterix Corporation, a life sciences company, engages in development and marketing of digital immunoassay platforms that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific regions. The company offers HD-X instrument, a protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection in an expanded range of applications.
Further Reading
Before you consider Quanterix, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Quanterix wasn't on the list.
While Quanterix currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
